Floatz logo

Busulfanum

T Lymphoblastic Leukemia/Lymphoma

First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the T Lymphoblastic Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Cytarabine
Princess Maxima Center for Pediatric Oncology
Phase 3BB
Cyclophosphamide
Children's Oncology Group
Phase 3BB
Prednisone
Children's Oncology Group
Phase 3BB
Etoposide
Children's Cancer Group, China
Phase 3BB
Decitabine
M.D. Anderson Cancer Center
Phase 3B

View all 50 →

Same molecule, other indications

Busulfanum is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →